| Species |
Human |
| Protein Construction |
| His |
TPM1 (Met1-Met284)_x000D_
Accession # NP_000357.3 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
34.26 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 34.26 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS, 150mM NaCl (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tropomyosin-1 (TPM1), a widely expressed actin-binding protein, is downregulated in many tumors and associated with cancer progression. TPM1 overexpression in RCC cell lines can induce tumor cell apoptosis via the p53-mediated mitochondrial pathway. Further studies are needed to fully elucidate the potential of TPM1 as a candidate for RCC targeted therapy in the future. |
| Synonyms |
C15orf13; TMSA; CMD1Y; CMH3; HTM-alpha; LVNC9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
